<DOC>
	<DOCNO>NCT00422877</DOCNO>
	<brief_summary>To evaluate objective response rate duration response weekly Taxoprexin® . To evaluate safety profile weekly Taxoprexin® patient population . To evaluate overall survival patient population . To evaluate time disease progression , time treatment failure patient primary liver cancer treat weekly Taxoprexin® Injection . To explore trough peak blood level Taxoprexin® paclitaxel patient .</brief_summary>
	<brief_title>Taxoprexin® Treatment Advanced Primary Cancers Liver</brief_title>
	<detailed_description>This Phase II open-label study weekly Taxoprexin® Injection patient advance primary cancer liver , include hepatocellular carcinoma ( HCC ) , carcinoma gallbladder biliary tract ( BTC ) , receive prior systemic cytotoxic therapy advance disease . Patients may previously receive radiation and/or systemic chemotherapy adjuvant therapy . Patients may treat previously taxane . Patients may previously treat two immunological and/or biologic agent ( e.g. , interferon , monoclonal antibody , tyrosine kinase inhibitor ) . Patients receive Taxoprexin® Injection dose 500mg/m2 ( 400mg/m2 patient elevate bilirubin baseline ) intravenously 1-hour infusion weekly first five week six week cycle . Treatment continue progression disease , intolerable toxicity , refusal continue treatment patient Investigator decision .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologic cytologic confirmation primary cancer liver , include HCC adenocarcinoma gallbladder bile duct advance ( unresectable and/or metastatic ) disease . 2 . Patients must least one measurable lesion RECIST criterion . 3 . Patients may receive two prior systemic noncytotoxic regimens disease . Prior treatment immunologic and/or biologic agent allow . 4 . At least 6 week ( 42 day ) since prior immunologic biologic therapy . 5 . At least 4 week ( 28 day ) since prior radiotherapy &gt; 20 % bone marrow prior adjuvant chemotherapy . 6 . Lesions use assess disease status may radiate , must progress radiation therapy . 7 . Patients must ECOG performance status 02 . 8 . Patients must least 18 year age . 9 . Patients must adequate liver renal function . 10 . Patients must adequate bone marrow function . 11 . Patients must sign informed consent form indicate aware investigational nature study keep policy institution . 1 . Patients receive prior therapy taxane . 2 . Patients past current history cancer entry diagnosis , except curatively treat nonmelanoma skin cancer carcinoma situ cervix cancer treat cure diseasefree survival longer 5 year . 3 . Patients symptomatic brain metastasis ( e ) . 4 . Patients pregnant nursing patient practice acceptable method birth control . Patients may breastfeed study . 5 . Patients active infection currently receive antiinfectious treatment ( e.g. , antibiotic , antiviral , antifungal ) . 6 . Patients current peripheral neuropathy etiology great grade one ( 1 ) . 7 . Patients unstable serious concurrent medical condition exclude . 8 . Patients know hypersensitivity Cremophor® . 9 . Patients one follow manifestation disease ineligible : bone lesion , leptomeningeal disease , ascites , pleural/pericardial effusion , carcinomatous lymphangitis , CNS metastases , lesion previously irradiate area show definite progression , disease infer laboratory test marker . 10 . Patients history Gilbert 's Syndrome . 11 . Patients must receive concurrent chemotherapy , radiotherapy , nonFDA approve nutritional supplement herbal preparation immunotherapy study . 12 . Known HIV disease infection . 13 . Patients receive ketoconazole , erythromycin , verapamil , diazepam , quinidine diltiazem . 14 . Patients must surgical procedure require hospitalization administration general anesthesia within past 28 day . 15 . Patients must receive prior systemic chemotherapy advance disease . Prior adjuvant systematic chemotherapy ( nontaxane contain ) allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Liver Cancer</keyword>
</DOC>